Tags

Type your tag names separated by a space and hit enter

Proteomic Approaches to Decipher Mechanisms Underlying Pathogenesis in Multiple Sclerosis Patients.
Proteomics 2019; 19(16):e1800335P

Abstract

Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease of the central nervous system (CNS). The cause of MS is unknown, with no effective therapies available to halt the progressive neurological disability. Development of new and improvement of existing therapeutic strategies therefore require a better understanding of MS pathogenesis, especially during the progressive phase of the disease. This can be achieved through development of biomarkers that can help to identify disease pathophysiology and monitor disease progression. Proteomics is a powerful and promising tool to accelerate biomarker detection and contribute to novel therapeutics. In this review, an overview of how proteomic technology using CNS tissues and biofluids from MS patients has provided important clues to the pathogenesis of MS is provided. Current publications, pitfalls, as well as directions of future research involving proteomic approaches to understand the pathogenesis of MS are discussed.

Authors+Show Affiliations

Department of Neurosciences, Cleveland Clinic, Cleveland, OH, 44195, USA.Department of Neurosciences, Cleveland Clinic, Cleveland, OH, 44195, USA.Department of Neurosciences, Cleveland Clinic, Cleveland, OH, 44195, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

31119864

Citation

Singh, Vaibhav, et al. "Proteomic Approaches to Decipher Mechanisms Underlying Pathogenesis in Multiple Sclerosis Patients." Proteomics, vol. 19, no. 16, 2019, pp. e1800335.
Singh V, Tripathi A, Dutta R. Proteomic Approaches to Decipher Mechanisms Underlying Pathogenesis in Multiple Sclerosis Patients. Proteomics. 2019;19(16):e1800335.
Singh, V., Tripathi, A., & Dutta, R. (2019). Proteomic Approaches to Decipher Mechanisms Underlying Pathogenesis in Multiple Sclerosis Patients. Proteomics, 19(16), pp. e1800335. doi:10.1002/pmic.201800335.
Singh V, Tripathi A, Dutta R. Proteomic Approaches to Decipher Mechanisms Underlying Pathogenesis in Multiple Sclerosis Patients. Proteomics. 2019;19(16):e1800335. PubMed PMID: 31119864.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Proteomic Approaches to Decipher Mechanisms Underlying Pathogenesis in Multiple Sclerosis Patients. AU - Singh,Vaibhav, AU - Tripathi,Ajai, AU - Dutta,Ranjan, Y1 - 2019/06/21/ PY - 2018/09/05/received PY - 2019/05/15/revised PY - 2020/08/01/pmc-release PY - 2019/5/24/pubmed PY - 2019/5/24/medline PY - 2019/5/24/entrez KW - biomarkers KW - central nervous system KW - multiple sclerosis KW - proteomics SP - e1800335 EP - e1800335 JF - Proteomics JO - Proteomics VL - 19 IS - 16 N2 - Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease of the central nervous system (CNS). The cause of MS is unknown, with no effective therapies available to halt the progressive neurological disability. Development of new and improvement of existing therapeutic strategies therefore require a better understanding of MS pathogenesis, especially during the progressive phase of the disease. This can be achieved through development of biomarkers that can help to identify disease pathophysiology and monitor disease progression. Proteomics is a powerful and promising tool to accelerate biomarker detection and contribute to novel therapeutics. In this review, an overview of how proteomic technology using CNS tissues and biofluids from MS patients has provided important clues to the pathogenesis of MS is provided. Current publications, pitfalls, as well as directions of future research involving proteomic approaches to understand the pathogenesis of MS are discussed. SN - 1615-9861 UR - https://www.unboundmedicine.com/medline/citation/31119864/Proteomic_approaches_to_decipher_mechanisms_underlying_pathogenesis_in_multiple_sclerosis_patients L2 - https://doi.org/10.1002/pmic.201800335 DB - PRIME DP - Unbound Medicine ER -